((自动化翻译由路透提供,请见免责声明 ))
路透12月9日 - Relmada Therapeutics 周一表示,它将中止为开发抑郁症药物而计划的两项后期研究,并探索包括出售在内的战略替代方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.